16. The compound of claim 1, wherein said compound is selected from the group consisting of



,



and



wherein R is CH_3 or ethyl, or R and R together form cyclopropyl, cyclopentyl, or pyran.

17. The compound of claim 1, wherein said compound has the following structure:



18. Use of an effective amount of a compound of claim 1 in the manufacture of a medicament for preventing, treating or ameliorating cancer or tumor metastasis in a mammal in need thereof.

19. Use of a combination of: 1) a pharmaceutically effective amount of a compound of Formula I or a polymorph, a geometric isomer, a stereoisomer, an enantiomer, a diastereomer, a solvate, an ester, a tautomer, a metabolite or a pharmaceutically acceptable salt thereof; and 2) a pharmaceutically effective amount of at least one additional anti-cancer agent in the manufacture of a mediament for treating cancer in a subject.

20. The use of claim 19, wherein the additional anti-cancer agent is selected from the group consisting of antimitotic agents, antimetabolite agents, HDAC inhibitors, proteosome inhibitors, immunotherapeutic agents, FLT-3 kinase inhibitors, and WNT pathway inhibitors.